You can helpexpand this article with text translated fromthe corresponding article in Japanese. (January 2025)Click [show] for important translation instructions. View a machine-translated version of the Japanese article. Machine translation, likeDeepL orGoogle Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Consideradding a topic to this template: there are already 1,382 articles in themain category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. Youmust providecopyright attribution in theedit summary accompanying your translation by providing aninterlanguage link to the source of your translation. A model attribution edit summary isContent in this edit is translated from the existing Japanese Wikipedia article at [[:ja:塩野義製薬]]; see its history for attribution. You may also add the template{{Translated|ja|塩野義製薬}} to thetalk page. For more guidance, seeWikipedia:Translation.

Shionogi & Co., Ltd.

Native name	塩野義製薬株式会社
Romanized name	Shionogi Seiyaku Kabushiki Kaisha
Company type	Public (K.K)
Traded as	TYO:4507 Nikkei 225 Component
Industry	Biotechnology &Pharmaceuticals
Founded	Osaka,Japan (March 17, 1878; 147 years ago (1878-03-17))
Founder	Gisaburo Shiono Sr.
Headquarters	1-8, Doshomachi 3-chome,Chuo-ku,Osaka 541-0045, Japan
Key people	Isao Teshirogi, Ph.D. (CEO andPresident)
Products	Diagnostics Medical devices Pharmaceuticals etc.
Revenue	¥ 426.684 billion (2022)[1]
Operating income	¥ 133.274 billion (2022)[1]
Net income	¥ 107.367 billion (2022)[1]
Total assets	¥ 768.120 billion (2022)[1]
Total equity	¥ 1,121.878 billion (2022)[1]
Number of employees	Consolidated : 6,082
Subsidiaries	Shinogi Healthcare Shinogi Pharma UMN Pharma
Website	Official website
Footnotes / references [2][3][1]

Shionogi & Company, Limited (塩野義製薬株式会社,Shionogi Seiyaku Kabushiki Kaisha) is a Japanesepharmaceutical company best known for developingCrestor. Medical supply and brand name also uses katakana (シオノギ).

Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are forhyperlipidaemia,antibiotics, andcancer medicines.

In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because ofantibiotic resistance and slow growth of the antibiotic market, it has teamed up with US basedSchering-Plough (merged in 2009 withMerck & Co) to become a sole marketing agent for its products in Japan.

Shionogi had supported the initial formation ofRanbaxy Pharmaceuticals, a generic manufacturer based inIndia. In 2012 the company became a partial owner ofViiV Healthcare, a pharmaceutical company specialising in the development of therapies forHIV.^[4]

The company is listed on theTokyo Stock Exchange andOsaka Securities Exchange and is constituent of theNikkei 225 stock index.^[5]

In June 2023, Shionogi announced its acquisition ofQpex Biopharma for approximately $140m.^[6]

• Avelox, antibacterialantiseptic that treats a number of infections.
• Claritin, An anti-histamine marketed in alliance withSchering-Plough.
• Crestor, cholesterol drug

  

  , marketing rights sold toAstraZeneca in 1998.^[7][8]
• Cymbalta, anSNRI class anti-depressant, marketed in alliance withEli Lilly.
• Differin (developed byGalderma), a topical retinoid foracne, marketed in Japan in alliance with Galderma.
• Fortamet
• Methylin
• Mogadon, a short-term treatment forinsomnia.
• Mulpleta, athrombopoietin receptor agonist.
• Osphena, an estrogen receptor agonist, marketing rights sold toDuchesnay in 2017.^[9]
• Symproic, aμ-opioid receptor antagonist, foropioid-induced constipation treatment.
• Xofluza, anendonuclease inhibitor, for influenza treatment.
• Ensitrelvir, the first Japanese domestic pill to treatCOVID-19.^[10]

• Asapiprant [Wikidata] (BGE-175), aDP1 receptor antagonist under development for treatment of COVID-19 in elderly patients and allergic rhinitis.^{[11][12][13][14][15]}

• Shionogi (and later Shinonogi Healthcare) has been the sponsor ofFuji Television Network, Inc.'s "Music Fair" since it started in 1964. In January 2025, Shionogi has decided to remove its name from the show, due to theFuji TV - Masahiro Nakai scandal. A Shionogi representative said in an interview, "I believe that Fuji Television should provide an explanation of the facts and future actions as soon as possible".^[16][17]
• Shionogi was a main sponsor ofTeam Lotus in the team's final years between 1991 and 1994.^[18]

• Official Website(in English)
• Official U.S. Website(in English)

• TOPIX 100
• Biotechnology companies of Japan
• Companies listed on the Osaka Exchange
• Companies listed on the Tokyo Stock Exchange
• Companies in the Nikkei 225
• Japanese brands
• Manufacturing companies based in Osaka
• Pharmaceutical companies established in 1878
• Pharmaceutical companies of Japan
• COVID-19 vaccine producers

• CS1 Spanish-language sources (es)
• CS1 Japanese-language sources (ja)
• Articles with short description
• Short description matches Wikidata
• Use dmy dates from October 2019
• Articles needing translation from Japanese Wikipedia
• Articles containing Japanese-language text
• Official website different in Wikidata and Wikipedia